Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel

Annals of Oncology

Volumn 19, Issue 3, 2008, Pages 420-432

  Aapro, M ^a   Abrahamsson, P A ^b   Body, J J ^c   Coleman, R E ^d   Colomer, R ^e   Costa, L ^f   Crino L ^g   Dirix, L ^h   Gnant, M ⁱ   Gralow, J ^j   Hadji, P ^k   Hortobagyi, G N ^l   Jonat, W ^m   Lipton, A ⁿ   Monnier, A ^o   Paterson, A H G ^p   Rizzoli, R ^q   Saad, F ^r   Thurlimann B ^s  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c JULES BORDET INSTITUTE   (Belgium)

^d WESTON PARK HOSPITAL   (United Kingdom)

^e MD ANDERSON CANCER CENTER   (Spain)

^f HOSPITAL DE SANTA MARIA   (Portugal)

^g Perugia Medical Hospital   (Italy)

^h SINT AUGUSTINUS HOSPITAL   (Belgium)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j UNIVERSITY OF WASHINGTON   (United States)

^k PHILIPPS UNIVERSITY MARBURG   (Germany)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^m UNIVERSITY OF KIEL   (Germany)

ⁿ PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^o Centre Hospitalier André Boulloche   (France)

^p UNIVERSITY OF CALGARY   (Canada)

^q UNIVERSITY HOSPITAL   (Switzerland)

^r UNIVERSITÉ DE MONTRÉAL   (Canada)

^s CANTONAL HOSPITAL ST GALLEN   (Switzerland)

more..

Author keywords

Bisphosphonates; Bone; Cancer; CTIBL; Metastases; SRE

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; COLECALCIFEROL; CORTICOSTEROID; DOCETAXEL; ETIDRONIC ACID; GLUCOCORTICOID; GONADORELIN; GOSERELIN; IBANDRONIC ACID; IBUPROFEN; LETROZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PAMIDRONIC ACID; PARACETAMOL; PLACEBO; PLATINUM COMPLEX; RISEDRONIC ACID; TAMOXIFEN; THALIDOMIDE; TILUDRONIC ACID; UNINDEXED DRUG; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANALGESIA; ARTHRALGIA; BONE DISEASE; BONE NECROSIS; BONE PAIN; BREAST CANCER; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; CREATININE CLEARANCE; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE KIDNEY FUNCTION RELATION; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG MONITORING; DRUG TOLERABILITY; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HORMONAL THERAPY; HUMAN; HYPOCALCEMIA; INJECTION PAIN; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LOW DRUG DOSE; LUNG CANCER; LYMPH NODE METASTASIS; METABOLIC BONE DISEASE; MULTIPLE CYCLE TREATMENT; MYALGIA; NEPHROTOXICITY; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; OVERALL SURVIVAL; PAGET BONE DISEASE; PATHOLOGIC FRACTURE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PHLEBITIS; PREVENTIVE DENTISTRY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SOLID TUMOR; STOMACH IRRITATION; SURVIVAL RATE; SWELLING; TREATMENT DURATION; ULCER PERFORATION; UVEITIS;

EID: 40149083563     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm442     Document Type: Review

References (154)

1. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002; 4: 30-34.
2. Civitelli R, Napoli N, Armamento-Villareal R. Use of intravenous bisphosphonates in osteoporosis. Curr Osteoporos Rep 2007; 5: 8-13.
3. Green JR, Bisphosphonates: Preclinical review, Oncologist 2004; 9 (Suppl 4): 3-13.
4. Rogers MJ, Brown RJ, Hodkin V et al. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun 1996; 224: 863-869.
5. Luckman SP, Hughes DE, Coxon FP et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581-589.
6. Goffinet M, Thoulouzan M, Pradines A et al. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 2006; 6: 60.
7. Coleman RE. Bisphosphonates: Clinical experience. Oncologist 2004; 9 (Suppl 4): 14-27.
8. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80: 1588-1594.
9. Body JJ. Current and future directions in medical therapy: hypercalcemia. Cancer 2000; 88: 3054-3058.
10. Body JJ. Hypercalcemia of malignancy. Semin Nephrol 2004; 24: 48-54.
11. Saad F, Olsson C, Schulman CC. Skeletal morbidity in men with prostate cancer: Quality-of-life considerations throughout the continuum of care. Eur Urol 2004; 46: 731-739 discussion 739-740.
12. Weinfurt KP, Castel LD, Li Y et al. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 2004; 42: 164-175.
13. Wardley A, Davidson N, Barrett-Lee P et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: A randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005; 92. 1869-1876.
14. Delea T, Langer C, McKiernan J et al, The cost of treatment of skeletal- related events in patients with bone metastases from lung cancer. Oncology 2004; 67: 390-396.
15. Gralow J, Tripathy D, Managing metastatic bone pain: The role of bisphosphonates. J Pain Symptom Manage 2007; 33: 462-472.
16. Botteman M, Barghout V, Stephens J et al. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 2006; 17: 1072-1082.
17. De Cock E, Hutton J, Canney P et al. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. Clin Ther 2005; 27: 1295-1310.
18. Souberbielle B, Williams R, McCloskey E. The cost-effectiveness of bisphosphonates in metastatic breast cancer: Letter to the editor in response to Botteman et al. 2006. Ann Oncol 2007; 18: 393.
19. Gnant MF, Mlineritsch B, Luschin-Elbengreuth G et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25: 820-828.
20. Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update. Semin Oncol 2006; 33: S13-S17.
21. Brufsky A, Harker WG, Beck JT et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25: 829-836.
22. Powles T, McCroskey E, Paterson A. Oral bisphosphonates as adjuvant therapy for operable breast cancer. Clin Cancer Res 2006; 12: 6301s-6304s.
23. Diel IJ. Bisphosphonates in the prevention of bone metastases: Current evidence. Semin Oncol 2001; 28: 75-80.
24. Coleman RE, Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-176.
25. Hei YJ, Saad F, Coleman RE, Chen YM. Fractures negatively affect survival in patients with bone metastases from breast cancer. Breast Cancer Res Treat 2005; 94: (Abstr-6036).
26. Kohno N, Aogi K, Minami H et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol 2005; 23: 3314-3321.
27. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases (Cochrane Review). The Cochrane Library. Chichester, UK: John Wiley & Sons 2004; 1-59.
28. Body JJ, Diel IJ, Bell R et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004; 111: 306-312.
29. Hortobagyi GN, Theriault RL, Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998; 16: 2038-2044.
30. Body JJ, Diel IJ, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14: 1399-1405.
31. Body JJ, Diel IJ, Lichinitser MR et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004; 90: 1133-1137.
32. Kristensen B, Ejlertsen B, Groenvold M et al. Oral clodronate in breast cancer patients with bone metastases: A randomized study. J Intern Med 1999; 246: 67-74.
33. Paterson AH, Powles TJ, Kanis JA et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer, J Clin Oncol 1993; 11: 59-65.
34. Tubiana-Hulin M, Beuzeboc P, Mauriac L et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 2001; 88: 701-707.
35. Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17: 846-854.
36. Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735-1744.
37. Pavlakis N, Schmidt R, Stockler M, Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005; CDO03474.
38. Body J-J. Breast cancer: Bisphosphonate therapy for metastatic bone disease. Clin Cancer Res 2006; 12: 6258s-6263s.
39. Lipton A, Theriault RL, Hortobagyi GN et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials, Cancer 2000; 88: 1082-1090.
40. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-387.
41. Rosen LS, Gordon DH, Dugan W Jr et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion, Cancer 2004; 100: 36-43.
42. Body JJ, Lichnnitser M, Tjulandin S et al. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann Oncol 2007; 18 (7): 1165-1170.
43. Paterson AH, Ernst DS, Powles TJ et al. Treatment of skeletal disease in breast cancer with clodronate. Bone 1991; 12 (Suppl 1): S25-S30.
44. Yuen KK, Shelley M, Sze WM et al. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev 2006; CD006250.
45. Elomaa I, Kylmala T, Tammela T et al. Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer. Int Urol Nephrol 1992; 24: 159-166.
46. Dearnaley DP, Sydes MR, Mason MD et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003; 95: 1300-1311.
47. Ernst DS, Brasher P, Hagen N et al. A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 1997; 13: 319-326.
48. Smith JA Jr. Palliation of painful bone metastases from prostate cancer using sodium etidronate: Results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 1989; 141: 85-87.
49. Heidenreich A, Elert A, Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 2002; 5: 231-235.
50. Heidenreich A, Ohlmann C, Body JJ. Ibandronate in metastatic bone pain. Semin Oncol 2004; 31: 67-72.
51. Small EJ, Smith MR, Seaman JJ et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003; 21: 4277-4284.
52. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882.
53. Saad F. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer 2005; 4: 31-37.
54. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
55. Ernst DS, Tannock IF, Winquist EW et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003; 21: 3335-3342.
56. Saad F, Gleason D, Murray R, Tchekmedyian S. Zoledronic acid reduces skeletal morbidity regardless of previous skeletal events in men with prostate cancer and bone metastases [poster]. Paris, France: Presented at: 21st Annual Congress of the European Association of Urology 2006 April5-8 (Abstr 141).
57. Saad F. Bisphosphonates can prevent skeletal complications of malignant bone disease from prostate cancer and renal cell carcinoma. Eur Urol Suppl 2007; 6: 683-688.
58. Rosen LS, Gordon D, Tchekmedyian S et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21: 3150-3157.
59. Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 2613-2621.
60. Zekri J, Ahmed N, Coleman RE, Hancock BW. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 2001; 19: 379-382.
61. Bell R. Efficacy of ibandronate in metastatic bone disease: Review of clinical data. Oncologist 2005; 10 (Suppl 1): 8-13.
62. Piga A, Bracci R, Ferretti B et al. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. J Exp Clin Cancer Res 1998; 17: 213-217.
63. Summary of product characteristics (SmPC) Clodronate, Bonefos®. Swissmedic (50957, 50958). 2006. http://www.kompendium.ch/ Search.aspx?lang=de.
64. Summary of product characteristics (SmPC) Ibandronate, Bondronat®. Swissmedic (53626, 56360, 57424). 2007. http://www.kompendium.ch/ Search.aspx?lang=de.
65. Emkey RD, Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006; 119: S18-S-24.
66. Cramer JA, Gold DT, Silverman SL et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007; 18 (8): 1023-1031.
67. Gold DT, Safi W, Trinh H. Patient preference and adherence: Comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006; 22: 2383-2391.
68. Cooper A, Drake J, Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: Results from the PERSIST study. Int J Clin Pract 2006; 60: 896-905.
69. Göl D. Poor persistency with oral bisphosphonates in cancer patients with bone metastasis. Proc Am Soc Clin Oncol 2004 (Abstr 8221).
70. Mangiapane S, Hoer A, Gothe H et al. Higher persistency with i.v. bisphosphonates in patients with bone metastasis. ASCO Meeting Abstracts 2006; 24: 18623.
71. Chem B, Joseph D, Joshua D et al. Bisphosphonate infusions: Patient preference, safety and clinic use. Support Care Cancer 2004; 12: 463-466.
72. Summary of product characteristics (SmPQ Zoledronic Acid, Zometa®. Swissmedic (56257). 2005. http://www.kompendium.ch/Search.aspx?lang=de.
73. Summary of product characteristics (SmPC) Pamidronate, Aredia®. Swissmedic (52092). 2005. http://www.kompendium.ch/Search.aspx?lang=de.
74. Bondronat (ibandronic acid), Summary of Product Characteristics, 5 (IA) (cU/1/96/012/004 and EU/1/96/009-013). Welwyn Garden City, UK: Roche Registration, Ltd. Updated on March 6, 2007 based on EMEA/H/C/101/IA/043.
75. Body JJ, Mancini I. Bisphosphonates for cancer patients: Why, how, and when? Support Care Cancer 2002; 10: 399-407.
76. Hirsh V, Tchekmedyian NS, Rosen LS et al. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: Analysis based on history of skeletal complications. Clin Lung Cancer 2004; 6: 170-174.
77. Clemons MJ, Dranitsaris G, Ooi WS et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 2006; 24; 4895-4900.
78. Clemons M, Dranitsaris G, Ooi W, Cole DE. A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat 2007.
79. Coleman RE, Major P, Lipton A et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledrionic acid. J Clin Oncol 2005; 23: 4925-4935.
80. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243s-6249s.
81. Cook RJ, Coleman R, Brown J et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer, Clin Cancer Res 2006; 12: 3361-3367.
82. Body JJ, Coleman R, Clezardin P et al. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 2007; 43: 852-858.
83. Weinfurt KP, Li Y, Castel LD et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005; 16: 579-584.
84. Chow SC, Ki FY. Statistical issues in quality-of-life assessment. J Biopharm Stat 1996; 6: 37-48.
85. Chow E, Hoskin P, van der Linden Y et al. Quality of life and symptom end points in palliative bone metastases trials, Clin Oncol (R Coll Radiol) 2006; 18: 67-69.
86. Chow E, Harris K, Tharmalingam S et al, Early phase in the development of a bone metastases quality of life module. Clin Oncol (R Coll Radiol) 2007; 19: S26.
87. WHO's pain relief ladder. http://www.who.int/cancer/palliative/ painladder/en/.
88. Body JJ. Bisphosphonates for metastatic bone pain. Support Care Cancer 1999; 7: 1-3.
89. Vassiliou V, Kalogeropoulou C, Christopoulos C et al. Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Int J Radiat Oncol Biol Phys 2007; 67: 264-272.
90. Vassiliou V, Kalogeropoulou C, Giannopoulou E et al. A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate. Clin Exp Metastasis 2007; 24 (3): 169-178.
91. Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 2001; 165: 136-140.
92. Mancini I, Dumon JC, Body JJ. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: A pilot study. J Clin Oncol 2004; 22: 3587-3592.
93. Daubine F, Le Gall C, Gasser J et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007; 99: 322-330.
94. Bauss F, Body JJ. Ibandronate in metastatic bone disease: A review of preclinical data. Anticancer Drugs 2005; 16: 107-118.
95. Jagdev SP, Coleman RE, Shipman CM et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel. Br J Cancer 2001; 84: 1126-1134.
96. Ullén A, Lennartsson L, Hjelm-Eriksson M et al. Additive/synergistic anti-tumoral effects on prostate cancer cells in vitro following treatment with a combination of gemcitabine and zoledronic acid. Proc Am Soc Clin Oncol 2003; 22: 432 (Abstr 1737).
97. Neville-Webbe HL, Evans CA, Coleman RE, Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro, Tumour Biol 2006; 27: 92-103.
98. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA et al. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005; 113: 364-371.
99. Vogt U, Bielawski KP, Bosse U, Schlotter CM. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/ metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/ paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 2004; 12: 1109-1114.
100. Journe F, Magne N, Chaboteaux C et al. Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines. Clin Exp Metastasis 2006; 23: 135-147.
101. Iuliano F, Molica S, Abruzzese E et al. Samarium-153Sm-EDTMP and zoledronic acid present synergistic action and are able to control pain and significantly improve QoL in elderly patients with MM. (Results of a phase II trial and 19 months follow up). J Clin Oncol (Meeting Abstracts) 2004; 22: 6737.
102. Dunstan C, Felsenberg D, Seibel MJ. Therapy Insight: The risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 2006; 4: 42-55.
103. Hewitt RE, Lissina A, Green AE et al. The bisphosphonate acute phase response: Rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 2005; 139: 101-111.
104. Adami S, Bhalla AK, Dorizzi R et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987; 41: 326-331.
105. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003; 349: 1676-1679; discussion 1676-1679.
106. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999; 21: 389-406.
107. Vogel CL, Yanagihara RH, Wood AJ et al. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 2004; 9: 687-695.
108. Pecherstorfer M, Diel IJ. Rapid administration of ibandronate does not affect renal functioning: Evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy. Support Care Cancer 2004; 12: 877-881.
109. Pecherstorfer M, Rivkin S, Body JJ et al. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: An open-label trial. Clin Drug Investig 2006; 26: 315-322.
110. von Moos R, Thürlimann B, Caspar CB et al. Renal safety of intravenous ibandronate 6mg infused over 15 or 60 minutes in patients with breast cancer and bone metastases: A randomized, open-label study. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25 (18 Suppl): (Abstr 1114).
111. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144: 753-761.
112. Van den Wyngaert T, Huizing MT, Vermorken JB. Bisphosphonates and osteonecrosis of the jaw: Cause and effect or a post hoc fallacy? Ann Oncol 2006; 17: 1197-1204.
113. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management. Oral Sung Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 433-441.
114. Lenz JH, Steiner-Krammer B, Schmidt W et al. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? J Craniomaxillofac Surg 2005; 33: 395-403.
115. Koka S, Clarke BL, Amin S et al. Oral bisphosphonate therapy and osteonecrosis of the jaw: What to tell the concerned patient. Int J Prosthodont 2007; 20: 115-122.
116. Weitzmar R, Sauter N, Erksen EF. Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients - May 2006, Crit Rev Oncol Hematol 2007; 62: 148-152.
117. Montazeri AH, Erskine JG, McQuaker IG. Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. Eur J Haematol 2007; 79: 69-71.
118. Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006; 35: 155-160.
119. Bilezikian JP. Osteonecrosis of the jaw - do bisphosphonates pose a risk? N Engl J Med 2006; 355: 2278-2281.
120. Zheng Y, Zhou H, Brennan K et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions: Of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 2007; 40: 471-478.
121. Friedlaender GE, Tross RB, Doganis AC et al. Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model. J Bone Joint Sung Am 1984; 66: 602-607.
122. Delmas PD, Fontana A, Bone loss induced by cancer treatment and its management. Eur J Cancer 1998; 34: 260-262.
123. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000; 18: 1570-1593.
124. Thurlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-2757.
125. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
126. Coleman RE, Banks LM, Girgis SI et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the intergroup Exemestane Study (IES): A randomsed controlled study. Lancet Oncol 2007; 8: 119-127.
127. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-164.
128. Eastell R, Hannon RA, Cuzick J et al. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006; 21: 1215-1223.
129. Kanis JA, McCloskey EV. Clodronate. Cancer 1997; 80: 1691-1695.
130. Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-955.
131. Cummings SR, Browner WS, Bauer D et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures' Research Group. N Engl J Med 1998; 339: 733-738.
132. Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park) 2005; 19: 651-658.
133. Saarto T, Blomqvist C, Valimaki M et al. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 1997; 75: 602-605.
134. Delmas PD, Balena R, Confravreux E et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. J Clin Oncol 1997; 15: 955-962.
135. Powles TJ, McCloskey E, Paterson AH et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 1998; 90: 704-708.
136. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: A randomized trial. Ann Intern Med 2007; 146: 416-424.
137. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al. Zoledronic acid effectively prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25 (7): 820-828.
138. Brufsky A, Harker WG, Beck JT et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25 (7): 829-836.
139. Brufsky A, Bundred N, Coleman R. An integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Breast Cancer Res Treat 2006; 100 (Suppl 1): S25.
140. Michaelson MD, Kaufman DS, Lee H et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 1038-1042.
141. Smith MR, Eastham J, Gleason DM et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-2012.
142. McCloskey E, Paterson AHG, Powles TJ. Oral clodronate maintains bone mass in women with primary breast cancer. J Clin Oncol 2005; 23 (Abstr 535).
143. McCloskey E, Paterson AHG, Powles TJ. Effects of oral clodronate (BONEFOS (R)) therapy on bone turnover and skeletal metastases in women with primary breast cancer. Breast Cancer Res Treat 2005; 94 (Suppl 1): 5 (Abstr 43).
144. Lester JE, Gutcher SA, Ellis SP et al. Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer: One-year results from the ARIBON study. J Clin Oncol (Meeting Abstracts) 2007; 25: (Abstr 553).
145. Aapro M, Hadji P, Brufsky A et al. Recommendation for the prevention of Aromatase Inhibitor associated Bone Loss in women with Breast Cancer. Submitted Poster Presentation, ECCO 14, 2007.
146. Diel IJ, Solomayer EF, Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-363.
147. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004; 43: 650-656.
148. Powles T, Paterson A, McCloskey E et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006; 8: R13.
149. Saarto T, Vehmanen L, Blomqvist C, Elomaa I. 10-year follow-up of the efficacy of clodronate on bone mineral density (BMD) in early stage breast cancer. J Clin Oncol ASCO Annual Meeting Proceedings Part I 2006; 24 (18 Suppl): (Abstr 676).
150. Jaschke A, Bastert G, Solomayer EF et al. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow - a longtime follow-up. J Clin Oncol (Meeting Abstracts) 2004; 22: 529.
151. Ha TC, Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer 2007; 96: 1796-1801.
152. Mystakidou K, Katsouda E, Parpa E et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005; 22: 195-201.
153. Rack W, Janni A, Schoberth C et al. Effect of zoledronate on persisting isolated tumor cells (ITC) in the bone marrow (BM) of patients without recurrence of early breast cancer. Proc Am Soc Clin Oncol 2004; 23 (Suppl): 843 (Abstract 9515).
154. Coleman R, Thorpe H, Cameron D et al. Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy - first safety data from the AZURE trial (BIG01/04) [poster] Presented at: 29th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 14-17, 2006 (Abstr 2080).